Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y

Journal of Immunology

Volumn 171, Issue 4, 2003, Pages 2109-2115

  Banda, Nirmal K ^a   Kraus, Damian M ^a   Muggli, Michele ^a   Bendele, Alison ^b   Holers, V Michael ^a   Arend, William P ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b BolderPATH   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COLLAGEN ANTIBODY; GAMMA INTERFERON; GENE PRODUCT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PROTEIN CRRY1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; CELL PROLIFERATION; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; COMPLEMENT INHIBITOR COMPLEMENT RECEPTOR 1 RELATED GENE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; GENE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SPLEEN CELL; SYNOVIUM; TRANSGENIC MOUSE; WILD TYPE;

EID: 0042134786     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.4.2109     Document Type: Article

References (38)

1. Luross, J. A., and N. A. Williams. 2001. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 103:407.
2. Trentham, D. E., R. A. Dynesius, and J. R. David. 1978. Passive transfer by cells of type II collagen-induced arthritis. J. Clin. Invest. 61:359.
3. Stuart, J. M., M. A. Cremer, A. S. Townes, and A. H. Kang. 1982. Type II collagen-induced arthritis in rats: passive transfer with serum and evidence that IgG anti-collagen antibodies can cause arthritis. J. Exp. Med. 155:1.
4. Morgan, K., R. B. Clague, M. J. Shaw, S. A. Firth, T. M. Twose, and P. J. L. Holt. 1981. Native type II collagen-induced arthritis in the rat: the effect of complement depletion by cobra venom factor. Arthritis Rheum. 24:1356.
5. Stuart, J. M., and F. J. Dixon. 1983. Serum transfer of collagen-induced arthritis in mice. J. Exp. Med. 158:378.
6. Kerwar, S. S., M. E. Englert, R. A. McReynolds, M. J. Landes, J. M. Lloyd, A. L. Oronsky, and F. J. Wilson. 1983. Type II collagen-induced arthritis: studies with purified anti-collagen immunoglobulin. Arthritis Rheum. 26:1120.
7. Goodfellow, R. M., A. S. Williams, J. L. Levin, B. D. Williams, and B. P. Morgan. 2000. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin. Exp. Immunol. 119:210.
8. Dreja, H., A. Annenkov, and Y. Chernajovsky. 2000. Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. Arthritis Rheum. 43:1698.
9. Hietala, M. A., I.-M. Jonsson, A. Tarkowski, S. Kleinau, and M. Pekna. 2002. Complement deficiency ameliorates collagen-induced arthritis in mice, J. Immunol. 169:454.
10. Watson, W. C., and A. S. Townes. 1985. Genetic susceptibility to murine collagen II autoimmune arthritis: proposed relationship to the IgG2 autoantibody subclass response, complement C3, major histocompatibility complex (MHC) and non-MHC loci. J. Exp. Med. 162:1878.
11. Banarjee, S., G. D. Anderson, H. S. Luthra, and C. S. David. 1989. Influence of complement C5 and Vβ T cell receptor mutations on susceptibility to collagen-induced arthritis. J. Immunol. 142:2237.
12. Reife, R. A., N. Loutis, W. C. Watson, K. A. Hasty, and J. M. Stuart. 1991. SWR mice are resistant to collagen-induced arthritis but produce potentially arthritogenic antibodies. Arthritis Rheum. 34:776.
13. Spinella, D. G., J. R. Jeffers, R. A. Reife, and J. M. Stuart. 1991. The role of C5 and T-cell receptor Vβ genes in susceptibility to collagen-induced arthritis. Immunogenetics 34:23.
14. Watson, W. C., P. S. Brown, J. A. Pitcock, and A. S. Townes. 1987. Passive transfer studies with type II collagen antibody in B10.D2/old and new line and C57BL/6 normal and beige (Chediak-Higashi) strains: evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive arthritis. Arthritis Rheum. 30:460.
15. Wang, Y., S. A. Rollins, J. A. Madri, and L. A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92:8955.
16. Wang, Y., J. Kristan, L. Hao, C. S. Lenkoski, Y. Shen, and L. A. Matis. 2000. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J. Immunol. 164:4340.
17. Smith, G. P., and R. A. G. Smith. Membrane-targeted complement inhibitors. 2001. Mol. Immunol. 38:249.
18. Mizuno, M., K. Nishikawa, O. B. Spiller, B. P. Morgan, N. Okada, H. Okada, and S. Matsuo. 2001. Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats. Arthritis Rheum. 44:2425.
19. Banda, N. K., D. Kraus, A. Vondracek, L. H. Huynh, A. Bendele, V. M. Holers, and W. P. Arend. 2002. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum. 46:3065.
20. Quigg, R. J., C. He, A. Lim, D. Berthiaume, J. J. Alexander, D. Kraus, and V. M. Holers. 1998. Transgenic mice overexpressing the complement inhibitor Crry as a soluble protein are protected from antibody-induced glomerular injury. J. Exp. Med. 188:1321.
21. Bendele, A. M., E. S. Chlipala, J. Sherrer, J. Frazier, G. Sennello, W. J. Rich, and C. K. Edwards III. 2000. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type 1 in animal models of rheumatoid arthritis. Arthritis Rheum. 43:2648.
22. Alexander, J. J., A. Lim, C. He, R. L. MacDonald, V. M. Holers, and R. J. Quigg. 1999. Renal, central nervous system and pancreatic overexpression of recombinant soluble Crry in transgenic mice: a novel means of protection from complement-mediated injury. Immunopharmacology 42:245.
23. Banda, N. K., A. Vondracek, D. Kraus, C. A. Dinarello, S.-H. Kim, A. Bendele, G. Senaldi, and W. P. Arend. 2003. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol. 170:2100.
24. b) mice: new insights into an important disease model of rheumatoid arthritis. Eur. J. Immunol. 30:1568.
25. Quigg, R. J., Y. Kozono, D. Berthiaume, A. Lim, D. J. Salant, A. Weinfeld, P. Griffin, E. Kremmer, and V. M. Holers. 1998. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol. 160:4553.
26. Kaya, Z., M. Afanasyeva, Y. Wang, K. M. Dohmen, J. Schlichting, T. Tretter, D. Fairweather, V. M. Holers, and N. R. Rose. 2001. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nature Immunol. 2:739.
27. de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Immunol. 174:1209.
28. Lacraz, S., L. P. Nicod, R. Chicheportiche, H. G. Welgus, and J.-M. Dayer. 1995. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 96:2304.
29. Parry, S. L., M. Sebbag, M. Feldmann, and F. M. Brennan. 1997. Contact with T cells modulates monocyte production: role of T cell membrane TNF-α. J. Immunol. 158:3673.
30. Segal, B. M., B. K. Dwyer, and E. M. Shevach. 1998. An interleukin (IL)-IL-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187:537.
31. Carroll, M. C. 1998. CD21/CD35 in B cell activation. Semin. Immunol. 10:279.
32. Fischer, M. B., M. Ma, N. C. Hsu, and M. C. Carroll. 1998. Local synthesis of C3 within the splenic lymphoid compartment can reconstitute the impaired immune response in C3-deficient mice. J. Immunol. 160:2619.
33. Molina, H., V. M. Holers, B. Li, Y.-F. Fang, S. Mariathasan, J. Goellner, J. Strauss-Schoenberger, R. W. Karr, and D. D. Chaplin. 1996. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA 93:3357.
34. Grant, E. P., D. Picarella, T. Burwell, T. Delaney, A. Groci, N. Avitahl, A. A. Humbles, J.-C. Gutierrez-Ramos, M. Briskin, C. Gerard, and A. J. Coyle. 2002. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J. Exp. Med. 196:1461.
35. Shushakova, N., J. Skokowa, J. Schulman, U. Baumann, J. Zwimer, R. E. Schmidt, and J. E. Gessner. 2002. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J. Clin. Invest. 110:1823.
36. Mizuno, M., K. Nishikawa, R. M. Goodfellow, S. J. Piddlesden, B. P. Morgan, and S. Matsuo. 1997. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue of rats. Arthritis Rheum. 40:527.
37. Linton, S. M., A. S. Williams, I. Dodd, R. Smith, B. D. Williams, and B. P. Morgan. 2000. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum. 43:2590.
38. Harris, C. L., A. S. Williams, S. M. Linton, and B. P. Morgan. 2002. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin. Exp. Immunol. 129:198.